Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HND039
- Development stage
- Unknown
- Lead developer
- Handa Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HND039 is a small molecule tyrosine kinase inhibitor (TKI) being developed by Handa Pharma for the treatment of oncology indications. The compound is currently in the early clinical development stage, specifically undergoing pilot bioavailability (BA) studies to evaluate its pharmacokinetic profile. Handa Pharma utilizes its proprietary drug delivery technologies to develop 505(b)(2) products, which are typically improved formulations of established medicines. HND039 is designed to leverage these platforms to optimize the delivery and performance of a TKI, potentially offering clinical advantages such as improved safety, efficacy, or patient compliance compared to existing reference products.
02
Targets
AXL (AXL receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on HND039.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HND039.